RxDoctor Payments Data

Foluso Ogunsile, MD

Hematology · Hollywood, FLNPI 1619234242

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Vertex at 50.5% of the total. Reporting peaked in 2022 at $4,866 and has fallen 98.2% since, to $85 in 2025.

$11,227in general payments, 2019–2025

Across 34 payments — averaging $330.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$6K
  • Global Blood Therapeutics, Inc.$4K
  • Novartis$2K
  • Novo Nordisk$111
  • Pfizer$85
  • Karyopharm Therapeutics Inc.$12
  • plus $9 from 1 others

What the payments were for

  • Consulting fees$5,57850%
  • Speaking & faculty fees$3,61532%
  • Travel & lodging$1,13810%
  • Food & beverage$8838%
  • Education$120%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,227 in reported general payments places this provider in the 70th percentile of 79 hematology providers in Florida.

See all hematology providers in Florida

Medicare billing

Part B allowed, 2024
$14,535
Medicare patients
36
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor18$200,033
Deferiprone (3 Times A Day)Deferiprone12$110,983
EndariGlutamine19$62,324
OxycontinOxycodone Hcl47$55,153
L-GlutamineGlutamine12$36,774
Deferasirox35$36,247
Xtampza ErOxycodone Myristate22$21,377
EliquisApixaban11$10,110
Oxycodone Hcl273$6,098
Morphine Sulfate ErMorphine Sulfate99$3,788
Hydroxyurea100$2,586
Methadone Hcl37$941
Morphine Sulfate24$880
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$679
Hydromorphone Hcl101$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Global Blood Therapeutics, Inc.Oxbryta$3,831$200,03318 claims
Emmaus Medical, Inc.Endari$9$62,32419 claims
PfizerEliquis$85$10,11011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 hematology providers in Florida.

Other hematology in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →